Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

36.99 +2.22 (+6.38%)
Streaming Delayed Price Updated: 2:01 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 206,032
Open 34.80
Bid (Size) 36.79 (100)
Ask (Size) 37.08 (100)
Prev. Close 34.77
Today's Range 34.10 - 37.80
52wk Range 12.21 - 40.96
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗
ANAB stock shows explosive revenue growth and strong technical setup, making it a top momentum pick for biotech investors. 
Via Chartmill
News headline image
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs. 
Via Benzinga

Performance

YTD
+176.9%
+176.9%
1 Month
+4.8%
+4.8%
3 Month
+84.8%
+84.8%
6 Month
+80.7%
+80.7%
1 Year
+95.9%
+95.9%

More News

Read More
News headline image
Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run ↗
Via Investor's Business Daily
News headline image
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level ↗
Via Stocktwits
Why Is Eli Lilly’s Stock Slipping Premarket? ↗
Via Stocktwits
News headline image
Analyst Expectations For AnaptysBio's Future ↗
Via Benzinga
News headline image
Analyst Expectations For AnaptysBio's Future ↗
Via Benzinga
News headline image
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
Here are the top movers in Tuesday's session. ↗
Via Chartmill
News headline image
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in September Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio (ANAB) Q2 Revenue Jumps 103% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗
Via Benzinga

Frequently Asked Questions

Is AnaptysBio, Inc. - Common Stock publicly traded?
Yes, AnaptysBio, Inc. - Common Stock is publicly traded.
What exchange does AnaptysBio, Inc. - Common Stock trade on?
AnaptysBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AnaptysBio, Inc. - Common Stock?
The ticker symbol for AnaptysBio, Inc. - Common Stock is ANAB on the Nasdaq Stock Market
What is the current price of AnaptysBio, Inc. - Common Stock?
The current price of AnaptysBio, Inc. - Common Stock is 36.99
When was AnaptysBio, Inc. - Common Stock last traded?
The last trade of AnaptysBio, Inc. - Common Stock was at 11/18/25 02:01 PM ET
What is the market capitalization of AnaptysBio, Inc. - Common Stock?
The market capitalization of AnaptysBio, Inc. - Common Stock is 1.01B
How many shares of AnaptysBio, Inc. - Common Stock are outstanding?
AnaptysBio, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.